Research programme: iMod.Fc protein therapeutics - aTyr Pharma
Latest Information Update: 19 Aug 2016
At a glance
- Originator aTyr Pharma
- Class Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pneumonia; Pulmonary fibrosis